233 related articles for article (PubMed ID: 30903422)
1. Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer.
Guo X; Liu M; Hou H; Liu S; Zhang X; Zhang Y; Wu P; Pang C; Wang J
Int J Clin Oncol; 2019 Aug; 24(8):957-965. PubMed ID: 30903422
[TBL] [Abstract][Full Text] [Related]
2. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
Moschini M; Zaffuto E; Karakiewicz PI; Andrea DD; Foerster B; Abufaraj M; Soria F; Mattei A; Montorsi F; Briganti A; Shariat SF
Eur Urol; 2019 Feb; 75(2):319-328. PubMed ID: 30293908
[TBL] [Abstract][Full Text] [Related]
3. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention.
Zelefsky MJ; Pei X; Teslova T; Kuk D; Magsanoc JM; Kollmeier M; Cox B; Zhang Z
BJU Int; 2012 Dec; 110(11):1696-701. PubMed ID: 22889401
[TBL] [Abstract][Full Text] [Related]
4. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
5. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients.
Bhojani N; Capitanio U; Suardi N; Jeldres C; Isbarn H; Shariat SF; Graefen M; Arjane P; Duclos A; Lattouf JB; Saad F; Valiquette L; Montorsi F; Perrotte P; Karakiewicz PI
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):342-8. PubMed ID: 20117287
[TBL] [Abstract][Full Text] [Related]
6. Commentary on "secondary cancers after intensity-modulated radiotherapy, brachytherapy, and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention." Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, Cox B, Zhang Z. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.: BJU Int 2012;110:1696-701. doi: 10.1111/j.1464-410X.2012.11385.x. [Epub 2012 Aug 13].
Gottschalk A
Urol Oncol; 2014 Feb; 32(2):209. PubMed ID: 24445290
[TBL] [Abstract][Full Text] [Related]
7. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer.
Zelefsky MJ; Housman DM; Pei X; Alicikus Z; Magsanoc JM; Dauer LT; St Germain J; Yamada Y; Kollmeier M; Cox B; Zhang Z
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):953-9. PubMed ID: 22172904
[TBL] [Abstract][Full Text] [Related]
8. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
[TBL] [Abstract][Full Text] [Related]
9. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
Krasnow RE; Rodríguez D; Nagle RT; Mossanen M; Kibel AS; Chang SL
Urol Oncol; 2018 Nov; 36(11):500.e11-500.e19. PubMed ID: 30249519
[TBL] [Abstract][Full Text] [Related]
10. External beam radiotherapy combination is a risk factor for bladder cancer in patients with prostate cancer treated with brachytherapy.
Minami T; Fujita K; Hashimoto M; Nishimoto M; Adomi S; Banno E; Nozawa M; Nose K; Yoshimura K; Inada M; Yokokawa M; Nakamatsu K; Uemura H
World J Urol; 2023 May; 41(5):1317-1321. PubMed ID: 37024557
[TBL] [Abstract][Full Text] [Related]
11. Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy.
Hamilton SN; Tyldesley S; Hamm J; Jiang WN; Keyes M; Pickles T; Lapointe V; Kahnamelli A; McKenzie M; Miller S; Morris WJ
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):934-41. PubMed ID: 25240272
[TBL] [Abstract][Full Text] [Related]
12. Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer.
Wang C; King CR; Kamrava M; Iwamoto KS; Chen AM; Low D; Kupelian PA; Steinberg ML
Radiother Oncol; 2017 Apr; 123(1):133-138. PubMed ID: 28187996
[TBL] [Abstract][Full Text] [Related]
13. The characteristics of bladder cancer after radiotherapy for prostate cancer.
Abern MR; Dude AM; Tsivian M; Coogan CL
Urol Oncol; 2013 Nov; 31(8):1628-34. PubMed ID: 22575239
[TBL] [Abstract][Full Text] [Related]
14. Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both.
Jarosek SL; Virnig BA; Chu H; Elliott SP
Eur Urol; 2015 Feb; 67(2):273-80. PubMed ID: 25217421
[TBL] [Abstract][Full Text] [Related]
15. Incidence and survival of secondary malignancies after external beam radiotherapy for prostate cancer in the SEER database.
Huynh MJ; Eng L; Ngo LH; Power NE; Kamran SC; Pierce TT; Lo AC
Can Urol Assoc J; 2024 Apr; 18(4):121-128. PubMed ID: 38381941
[TBL] [Abstract][Full Text] [Related]
16. Incidence of bladder cancer after radiation for prostate cancer as a function of time and radiation modality.
Keehn A; Ludmir E; Taylor J; Rabbani F
World J Urol; 2017 May; 35(5):713-720. PubMed ID: 27629559
[TBL] [Abstract][Full Text] [Related]
17. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
[TBL] [Abstract][Full Text] [Related]
18. Second cancers in radically treated Norwegian prostate cancer patients.
Aksnessæther BY; Lund JÅ; Myklebust TÅ; Klepp OH; Skovlund E; Roth Hoff S; Solberg A
Acta Oncol; 2019 Jun; 58(6):838-844. PubMed ID: 30905229
[No Abstract] [Full Text] [Related]
19. Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: A population-based analysis.
Knipper S; Palumbo C; Pecoraro A; Rosiello G; Tian Z; Briganti A; Zorn KC; Saad F; Tilki D; Graefen M; Karakiewicz PI
Urol Oncol; 2020 Mar; 38(3):79.e9-79.e14. PubMed ID: 31653563
[TBL] [Abstract][Full Text] [Related]
20. Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients.
Hoeh B; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Chierigo F; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Terrone C; Shariat SF; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
Prostate; 2022 Jan; 82(1):120-131. PubMed ID: 34662443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
